Clinical Trial Update: Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating CAT-8015 immunotoxin in patients with chronic lymphocytic leukemia, prolymphocytic leukemia, or small lymphocytic lymphoma with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CAT-8015 immunotoxin (CAT-8015)

Snippet

Sponsor: Cambridge Antibody Technology | Conditions: Leukemia | Phase 1 | Status: UNKNOWN